Systematic Genetic Testing For Personalised Ovarian Cancer Therapy
Research type
Research Study
Full title
Systematic Genetic Testing for Personalised Ovarian cancer Therapy (SIGNPOsT)
IRAS ID
213653
Contact name
Ranjit Manchanda
Contact email
Sponsor organisation
Queen Mary, University of London
ISRCTN Number
ISRCTN16988857
Duration of Study in the UK
12 years, 0 months, 0 days
Research summary
In the UK, around 7000 women are diagnosed with ovarian cancer and 4000 women die from it every year. The commonest type is called epithelial ovarian cancers (EOC). Around 1 in 10 EOC are due to inheritable genetic alterations. BRCA1 and BRCA2 are the most well-known of these alterations. More recently, newer genes like RAD51C, RAD51D and BRIP1 have been identified. They moderately increase the risk of developing ovarian cancer. Together these account for most of their known genetic risk. Genetic testing for these genes is now offered clinically to women with EOC. This genetic test will be done both, in blood and tumour tissue. Women over the age of 18, with a diagnosis of epithelial ovarian cancer /fallopian tube cancer/ primary peritoneal cancer, will be invited to participate in the study.
We plan to evaluate patient experience and acceptability of testing for ovarian cancer genes. This study will look at the impact of genetic testing on psychological health, emotional wellbeing and quality of life. Participants will also complete questionnaires on satisfaction and regret. The detection rate of genetic alterations will be identified.
Consenting participants will be asked to provide health-related information, a blood sample, and a sample of the ovarian tumour tissue. These will be used to detect genetic and non-genetic markers. It will help improve our understanding of disease. This will help develop models and strategies for risk prediction, prevention, early detection, treatment and prediction of cancer outcomes.
REC name
London - Riverside Research Ethics Committee
REC reference
17/LO/0405
Date of REC Opinion
29 Mar 2017
REC opinion
Further Information Favourable Opinion